[Primary sclerosing cholangitis--tests with ubiquitin treatment. Case report].
Treatment of chronic liver disease, including primary sclerosing cholangitis (CSP) is a difficult and still not fully solved problem. Both monotherapy and combined pharmacological therapy have shown little effect in inhibiting the disease process and preventing complications. The objectives of ubiquitin biotherapy were restitution of the immune system and inhibition of the disease process along with the stimulation of regenerative processes of the liver. In 1994 in Gastroenterological Clinic attempts at ubiquitin biotherapy were made with the use of thymus extract (TFX-JELFA ini.), which proved to be the ubiquitin preparation that was not only active in the immune system but also played a significant role in regenerative and adjuvant processes. It has been shown that ubiquitins play an essential role in proteolysis of proteins, their intracellular elimination and in the apoptosis. The early results of the clinical observations and laboratory tests indicate a gradual improvement and inhibition of the disease process the patient with CSP.
Ciećko-Michalska
I
I
Kliniki Gastroenterologii, Wydziału Lekarskiego, Uniwersytetu Jagiellońskiego w Krakowie.
Bogdał
J
J
Turowski
G
G
D000328:Adult; D002758:Cholangiography; D015209:Cholangitis, Sclerosing / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D008297:Male; D014452:Ubiquitins / Q000627:therapeutic use*
D014452:Ubiquitins